Avatar
Imadreamer

0 Following 1 Followers
99
Individual stocks can enjoy head-turning rallies over short periods of time. As of this writing, for example, the top stock in the S&P 500 has risen by just under 200% so far in 2018.

But the real life-changing returns occur over time frames that are measured in years or even decades. So, with that ultra-long-term focus in mind, we asked three Motley Fool contributors to highlight a few stocks with unusually strong outlooks. Here's why NVIDIA (NASDAQ:NVDA), Constellation Brands (NYSE:STZ), and Stanley Black & Decker (NYSE:SWK) made that list.

An electronics maker for the ages
Nicholas Rossolillo (NVIDIA): I've always been a fan of the semiconductor industry. I think semiconductors are building blocks of the future -- a modern-day commodity of sorts -- so one of my first individual stock purchases over a decade ago was a chipmaker. Unfortunately, it wasn't NVIDIA. The maker of graphics processing units (GPUs) didn't hit my buy-list radar until much later as I never saw a future f
Read More
or the company outside of the video game industry.
129
“Ad blocking hasn’t vanished. It’s still a threat that can’t be forgotten. Publishers still need to find a route forward.”
104
A team of researchers from the U.K., Germany and Russia has found evidence of magnetism at the edges of graphene. In their paper published in the journal Nature, the researchers describe how they made their discovery and why they believe it is important.
76
Glioblastoma multiforme, a type of brain tumor, is one of the most difficult-to-treat cancers. Only a handful of drugs are approved to treat glioblastoma, and the median life expectancy for patients diagnosed with the disease is less than 15 months.

MIT researchers have now devised a new drug-delivering nanoparticle that could offer a better way to treat glioblastoma. The particles, which carry two different drugs, are designed so that they can easily cross the blood-brain barrier and bind directly to tumor cells. One drug damages tumor cells' DNA, while the other interferes with the systems cells normally use to repair such damage.
81
Let’s be honest, the RED Hydrogen One is destined to be a niche product. With a “holographic display” and a $1,200 starting price point, the thing wasn’t really designed with mainstream consumers in mind. An announcement of a forthcoming camera from the company doesn’t do a lot to change that, but it does shed a bit more light on who, precisely, the company is targeting here.